Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Victoria Sanz-Moreno: Rho together for cancer research.

O'Donnell MA.

J Cell Biol. 2018 Jun 4;217(6):1885-1886. doi: 10.1083/jcb.201805043. Epub 2018 May 18.

PMID:
29777025
2.

Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study.

Kogan P, Xu S, Wang Y, O'Donnell MA, Lutgendorf SK, Bradley CS, Schrepf A, Kreder KJ, Luo Y.

Sci Rep. 2018 Apr 26;8(1):6573. doi: 10.1038/s41598-018-24833-x.

3.

Tamas Balla: Leading the way with phosphoinositides.

O'Donnell MA.

J Cell Biol. 2018 Apr 2;217(4):1161-1162. doi: 10.1083/jcb.201803039. Epub 2018 Mar 16.

PMID:
29549128
4.

Laura Lackner: Passing on the scientific baton.

O'Donnell MA.

J Cell Biol. 2018 Mar 5;217(3):797-798. doi: 10.1083/jcb.201802048. Epub 2018 Feb 22.

PMID:
29472385
5.

Peptide-Mediated Targeting Mesoporous Silica Nanoparticles: A Novel Tool for Fighting Bladder Cancer.

Sweeney SK, Luo Y, O'Donnell MA, Assouline JG.

J Biomed Nanotechnol. 2017 Feb;13(2):232-42.

PMID:
29377654
6.

Bao-Liang Song: Loving biology in the time of cholesterol.

O'Donnell MA.

J Cell Biol. 2018 Feb 5;217(2):433-434. doi: 10.1083/jcb.201801066. Epub 2018 Jan 18.

PMID:
29348147
7.

Danica Chen: From early learning to aging research.

O'Donnell MA.

J Cell Biol. 2018 Jan 2;217(1):7-8. doi: 10.1083/jcb.201712043. Epub 2017 Dec 14.

PMID:
29242211
8.

Nasser Rusan: Scoping out centrosomes.

O'Donnell MA.

J Cell Biol. 2017 Dec 4;216(12):3889-3890. doi: 10.1083/jcb.201711049. Epub 2017 Nov 17.

9.

Complex relationships between shallow muddy benthic assemblages, sediment chemistry and toxicity in estuaries in southern New South Wales, Australia.

Birch GF, O'Donnell MA, McCready S.

Mar Pollut Bull. 2018 Apr;129(2):573-591. doi: 10.1016/j.marpolbul.2017.10.033. Epub 2017 Oct 28.

PMID:
29089114
10.

Ling-Ling Chen: Shaping a career in RNA biology.

O'Donnell MA.

J Cell Biol. 2017 Nov 6;216(11):3426-3427. doi: 10.1083/jcb.201710082. Epub 2017 Oct 27.

11.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA.

Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18. Review.

PMID:
29055653
12.

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE.

J Immunother Cancer. 2017 Sep 28;5(1):80. doi: 10.1186/s40425-017-0280-z. No abstract available.

13.

Margot Quinlan: Muscling in on oogenesis.

O'Donnell MA.

J Cell Biol. 2017 Oct 2;216(10):2992-2993. doi: 10.1083/jcb.201709035. Epub 2017 Sep 22.

14.

Yaron Fuchs: Exploring the mysterious mixture of life and death.

O'Donnell MA.

J Cell Biol. 2017 Sep 4;216(9):2600-2601. doi: 10.1083/jcb.201708079. Epub 2017 Aug 17.

15.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE.

J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0. Erratum in: J Immunother Cancer. 2017 Sep 28;5(1):80.

16.

Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.

Steinberg RL, Nepple KG, Velaer KN, Thomas LJ, O'Donnell MA.

Urol Oncol. 2017 Dec;35(12):670.e7-670.e14. doi: 10.1016/j.urolonc.2017.07.024. Epub 2017 Aug 8.

PMID:
28801026
17.

Ann Miller: Shaping cells and scientists.

O'Donnell MA.

J Cell Biol. 2017 Jul 21. pii: jcb.201707079. doi: 10.1083/jcb.201707079. [Epub ahead of print]

18.

Jonathan Kagan: A cell biologist's view of immunity.

O'Donnell MA.

J Cell Biol. 2017 Jun 5;216(6):1502-1503. doi: 10.1083/jcb.201705065. Epub 2017 May 23.

19.

Erin Goley: Catching the bug for studying the cytoskeleton.

O'Donnell MA.

J Cell Biol. 2017 Mar 6;216(3):528-529. doi: 10.1083/jcb.201702053. Epub 2017 Feb 24.

20.

Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.

Steinberg RL, Brooks NA, Thomas LJ, Mott SL, O'Donnell MA.

Urol Oncol. 2017 May;35(5):201-207. doi: 10.1016/j.urolonc.2016.11.016. Epub 2016 Dec 29.

PMID:
28041998
21.

Analysis of Temperature Variability in Medication Storage Compartments in Emergency Transport Helicopters.

O'Donnell MA, Whitfield J.

Air Med J. 2016 Nov - Dec;35(6):360-364. doi: 10.1016/j.amj.2016.08.002. Epub 2016 Oct 22.

PMID:
27894560
22.

Job Dekker: Hitting the scientific hi-Cs.

O'Donnell MA.

J Cell Biol. 2016 Nov 21;215(4):434-435. Epub 2016 Nov 14. No abstract available.

23.

Katja Röper: Deciphering tissue origami.

O'Donnell MA.

J Cell Biol. 2016 Oct 24;215(2):140-141. No abstract available.

24.

Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.

Kaelberer JB, O'Donnell MA, Mitchell DL, Snow AN, Mott SL, Buatti JM, Smith MC, Watkins JM.

Prostate Int. 2016 Sep;4(3):107-12. doi: 10.1016/j.prnil.2016.06.002. Epub 2016 Jun 23.

25.

Bladder cancer will grow anywhere: report of a urothelial carcinoma drop metastasis to the vagina and literature review.

Uhlman MA, Bevill MD, Goodheart MJ, Brown JA, O'Donnell MA.

Can J Urol. 2016 Aug;23(4):8379-81.

PMID:
27544563
26.
27.
28.

Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

Velaer KN, Steinberg RL, Thomas LJ, O'Donnell MA, Nepple KG.

Curr Urol Rep. 2016 May;17(5):38. doi: 10.1007/s11934-016-0594-2. Review.

PMID:
26968418
29.

Inflammation and Symptom Change in Interstitial Cystitis or Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study.

Schrepf A, O'Donnell MA, Luo Y, Bradley CS, Kreder KJ, Lutgendorf SK.

Urology. 2016 Apr;90:56-61. doi: 10.1016/j.urology.2015.12.040. Epub 2016 Jan 6.

30.

Treatment options in non-muscle-invasive bladder cancer after BCG failure.

Brooks NA, O'Donnell MA.

Indian J Urol. 2015 Oct-Dec;31(4):312-9. doi: 10.4103/0970-1591.166475. Review.

31.

Concise Synthesis of Annulated Pyrido[3,4-b]indoles via Rh(I)-Catalyzed Cyclization.

Varelas JG, Khanal S, O'Donnell MA, Mulcahy SP.

Org Lett. 2015 Nov 6;17(21):5512-4. doi: 10.1021/acs.orglett.5b02807. Epub 2015 Oct 23.

PMID:
26495834
32.

Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy.

Moriarty MA, Uhlman MA, Bing MT, O'Donnell MA, Brown JA, Tracy CR, Deorah S, Nepple KG, Gupta A.

BMC Urol. 2015 May 28;15:45. doi: 10.1186/s12894-015-0039-0.

33.

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.

Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA 3rd.

Nat Rev Urol. 2015 Apr;12(4):225-35. doi: 10.1038/nrurol.2015.58. Epub 2015 Mar 24. Review.

PMID:
25800393
34.

Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.

Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z.

J Urol. 2015 Jul;194(1):230-7. doi: 10.1016/j.juro.2015.02.036. Epub 2015 Feb 11.

35.
36.
37.

Morbidity and mortality of octogenarians following open radical cystectomy using a standardized reporting system.

Berneking AD, Rosevear HM, Askeland EJ, Newton MR, O'Donnell MA, Brown JA.

Can J Urol. 2013 Aug;20(4):6826-31.

PMID:
23930606
38.

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.

39.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28. Review.

PMID:
23628309
40.

New imaging techniques for non-muscle invasive bladder cancer: ready for primetime.

Gillespie JA, O'Donnell MA.

Urol Clin North Am. 2013 May;40(2):271-9. doi: 10.1016/j.ucl.2013.01.014. Epub 2013 Mar 7.

PMID:
23540784
41.

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.

Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O'Donnell MA.

Urol Oncol. 2014 Jan;32(1):35.e15-9. doi: 10.1016/j.urolonc.2013.01.009. Epub 2013 Mar 17.

42.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF.

J Urol. 2013 Sep;190(3):850-6. doi: 10.1016/j.juro.2013.03.030. Epub 2013 Mar 15.

43.

NEMO inhibits programmed necrosis in an NFκB-independent manner by restraining RIP1.

O'Donnell MA, Hase H, Legarda D, Ting AT.

PLoS One. 2012;7(7):e41238. doi: 10.1371/journal.pone.0041238. Epub 2012 Jul 26.

44.

Bladder Cancer Immunotherapy: BCG and Beyond.

Askeland EJ, Newton MR, O'Donnell MA, Luo Y.

Adv Urol. 2012;2012:181987. doi: 10.1155/2012/181987. Epub 2012 Jun 20.

45.

Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer.

Lightfoot AJ, Rosevear HM, Nepple KG, O'Donnell MA.

Int J Urol. 2012 Nov;19(11):988-93. doi: 10.1111/j.1442-2042.2012.03089.x. Epub 2012 Jul 4.

46.

Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.

Bockholt NA, Knudson MJ, Henning JR, Maymí JL, Weady P, Smith GJ 3rd, Eisenbraun MD, Fraser JD, O'Donnell MA, Luo Y.

J Urol. 2012 Jun;187(6):2228-35. doi: 10.1016/j.juro.2012.01.030. Epub 2012 Apr 13.

PMID:
22503050
47.

NFκB and ubiquitination: partners in disarming RIPK1-mediated cell death.

O'Donnell MA, Ting AT.

Immunol Res. 2012 Dec;54(1-3):214-26. doi: 10.1007/s12026-012-8321-7. Review.

PMID:
22477525
48.

Rubin H. Flocks and colloidal gold treatments for prostate cancer.

Rosevear HM, Lightfoot AJ, O'Donnell MA, Platz CE, Loening SA, Hawtrey CE.

ScientificWorldJournal. 2011;11:1560-7. doi: 10.1100/tsw.2011.145.. Epub 2011 Aug 16.

49.

Caspase 8 inhibits programmed necrosis by processing CYLD.

O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, Green DR, Ting AT.

Nat Cell Biol. 2011 Oct 30;13(12):1437-42. doi: 10.1038/ncb2362.

50.

Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Luo Y, Henning J, O'Donnell MA.

Clin Dev Immunol. 2011;2011:728930. doi: 10.1155/2011/728930. Epub 2011 Sep 15. Review.

Supplemental Content

Loading ...
Support Center